Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)
This rollover study will provide open-label treatment with cenicriviroc and will assess the long-term safety of continued treatment with cenicriviroc in participants who participated in either the CENTAUR study 652-2-203 [NCT02217475] or the AURORA study [NCT03028740].
Inclusion Criteria:
Exclusion Criteria:
San Diego, California 92093, United States
Tampa, Florida 33606, United States
Houston, Texas 77030, United States
Adelaide, South Australia 5000, Australia
Cologne, 50937, Germany
Hamburg, 20246, Germany